One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Menopause: a turning point for women's health
doi : 10.1016/S2213-8587(22)00142-5
Volume 10, Issue 6, June 2022, Page 373
Tirzepatide adds hepatoprotection to its armoury
GiovanniTarghera
SURPASSing the current dogma: is our framework shifting?
Natasha PMalkaniaVanita RArodaa
Postsurgical radioiodine ablation in low-risk differentiated thyroid cancer
FurioPacinia
Decision making in differences of sex development/intersex care in the USA: bridging advocacy and family-centred care
David ESandbergaEricVilainbcd
Osilodrostat for the treatment of Cushing's disease: efficacy, stability, and persistence
OlivierChabreaMarieMullerbJustineCristanteaJean-LucCracowskicEmmanuelGayd
Osilodrostat for the treatment of Cushing's disease: efficacy, stability, and persistence – Authors' reply
MariaFleseriuaFredericCastinettibcMônicaGadelhadAndreaGiustinaeAndréLacroixfShlomoMelmedgJohnNewell-PricehRosarioPivonelloiMartinReinckejBeverly M KBillerk“Consensus on diagnosis and management of Cushing's disease: a guideline update�
Hot topics on insulin access: the issue of thermostability
TalhaBurki
Singapore's “War on Diabetes�
Yong MongBeeaE ShyongTaibTien YWongcd
Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial
ProfAmaliaGastaldelliPhDaProfKennethCusiMDbLauraFernández LandóMDcRossBrayPhDcBramBrouwersPhDcÃ�ngelRodrÃguezMDd
Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial
TadejBattelinoMDaRichard MBergenstalMDbAngelRodrÃguezMDcLauraFernández LandóMDcRossBrayPhDcZhentaoTongPhDcKatelynBrownPharmDc
Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial
TimHeiseMDaAndreaMariPhDbProfJ HansDeVriesMDaShwetaUrvaPhDcJingLiPhDcEdward JohnPrattMDcTamerCoskunMDcMelissa KThomasMDcKieren JMatherMDcAxelHauptMDcZvonkoMilicevicMDc
Achievement of guideline recommended diabetes treatment targets and health habits in people with self-reported diabetes in India (ICMR-INDIAB-13): a national cross-sectional study
Ranjit MohanAnjanaMDaRanjitUnnikrishnanMDaMohanDeepaPhDbUlagamathesanVenkatesanMPHcRajendraPradeepaPhDdShashankJoshiMDeBanshiSabooMDfAshok KumarDasMDgSaritaBajajDMhAnilBhansaliMDiSri VenkataMadhuMDjVinay KumarDhandhaniaMDkPuthiyaveettil KottayamJabbarMDlSunil MJainMDmArvindGuptaMDnSubhankarChowdhuryMDoMohammed KAliMDbpElangovanNirmalMBAd…ViswanathanMohan
Menopause: a cardiometabolic transition
ProfRossella ENappiMDabProfPeterChedrauiMDcProfIreneLambrinoudakiMDdProfTommasoSimonciniMDe
Management of menopause: a view towards prevention
ProfRoger ALoboMDaProfAnneGompelMDb
